Feasibility/Phase II Study of hu14.18-IL2 Immunocytokine + GM-CSF and Isotretinoin in Patients With Relapsed or Refractory Neuroblastoma
Phase of Trial: Phase II
Latest Information Update: 08 Jul 2017
At a glance
- Drugs Isotretinoin (Primary) ; Monoclonal antibody ch14 18 interleukin-2 fusion protein (Primary) ; Sargramostim (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- 11 May 2016 Status changed from active, no longer recruiting to completed.
- 11 Jun 2013 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Aug 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.